JPS6157808B2 - - Google Patents
Info
- Publication number
- JPS6157808B2 JPS6157808B2 JP2227880A JP2227880A JPS6157808B2 JP S6157808 B2 JPS6157808 B2 JP S6157808B2 JP 2227880 A JP2227880 A JP 2227880A JP 2227880 A JP2227880 A JP 2227880A JP S6157808 B2 JPS6157808 B2 JP S6157808B2
- Authority
- JP
- Japan
- Prior art keywords
- cardiac
- effects
- effect
- observed
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000496 cardiotonic agent Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 description 23
- 230000000747 cardiac effect Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000002964 excitative effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 241000599931 Paris quadrifolia Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 206010060891 General symptom Diseases 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- -1 L-rhamnopyranosyl Chemical group 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940097217 cardiac glycoside Drugs 0.000 description 3
- 239000002368 cardiac glycoside Substances 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229930002534 steroid glycoside Natural products 0.000 description 3
- 150000008143 steroidal glycosides Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FBFJAXUYHGSVFN-IYUYFXHASA-N 68124-04-9 Chemical compound C([C@@]12[C@H]([C@@]3([C@@]4(C)CC[C@@H]5[C@@]6(C)CC[C@@H](CC6=CC[C@H]5[C@@H]4C[C@@H]3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@H](O)[C@@H](O[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)[C@H](C)O3)O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O)C)C[C@@H](C)CO1 FBFJAXUYHGSVFN-IYUYFXHASA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000208011 Digitalis Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000001699 lower leg Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- SYYHBUHOUUETMI-WJOMMTHPSA-N pennogenin Chemical compound C([C@@]12[C@H]([C@@]3([C@@]4(C)CC[C@@H]5[C@@]6(C)CC[C@H](O)CC6=CC[C@H]5[C@@H]4C[C@@H]3O2)O)C)C[C@@H](C)CO1 SYYHBUHOUUETMI-WJOMMTHPSA-N 0.000 description 2
- GZMJEZQPYGGHGJ-UHFFFAOYSA-N pennogenin tetraglycoside Natural products O1C2CC3C4CC=C5CC(OC6C(C(O)C(O)C(CO)O6)OC6C(C(O)C(OC7C(C(O)C(OC8C(C(O)C(O)C(C)O8)O)C(C)O7)O)C(C)O6)O)CCC5(C)C4CCC3(C)C2(O)C(C)C21CCC(C)CO2 GZMJEZQPYGGHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229960003279 thiopental Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- TYYDXNISHGVDGA-UHFFFAOYSA-N Corotoxigenin Natural products CC12CCC3C(CCC4CC(O)CCC34C=O)C1CCC2C5=CC(=O)OC5 TYYDXNISHGVDGA-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000006064 Heloniopsis orientalis Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- GMBQZIIUCVWOCD-UQHLGXRBSA-N Isosarsasapogenin Natural products O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 241000555684 Paris verticillata Species 0.000 description 1
- SYYHBUHOUUETMI-UHFFFAOYSA-N Pennogenin Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CCC3(C)C2(O)C(C)C21CCC(C)CO2 SYYHBUHOUUETMI-UHFFFAOYSA-N 0.000 description 1
- 241000270934 Rana catesbeiana Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 241000245029 Trillium camschatcense Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000037000 normothermia Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2227880A JPS56120700A (en) | 1980-02-26 | 1980-02-26 | Cardiac stimmulant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2227880A JPS56120700A (en) | 1980-02-26 | 1980-02-26 | Cardiac stimmulant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56120700A JPS56120700A (en) | 1981-09-22 |
| JPS6157808B2 true JPS6157808B2 (US08197722-20120612-C00042.png) | 1986-12-09 |
Family
ID=12078287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2227880A Granted JPS56120700A (en) | 1980-02-26 | 1980-02-26 | Cardiac stimmulant |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56120700A (US08197722-20120612-C00042.png) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648430A (zh) * | 2015-10-22 | 2018-02-02 | 江西中医药大学 | 一种含延龄草甾体皂苷类有效成分胶囊制剂的制备方法及其在制备各类药物中的应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0650186U (ja) * | 1992-12-18 | 1994-07-08 | 鹿島建設株式会社 | 設備プレート |
| CN1121722A (zh) * | 1993-04-28 | 1996-05-01 | 美国辉瑞有限公司 | 螺甾烷基苷结晶-水合物 |
| CN100420444C (zh) * | 2005-06-17 | 2008-09-24 | 云南白药集团股份有限公司 | 偏诺皂苷类化合物液态分子分散制剂 |
| CN105232891B (zh) * | 2015-10-23 | 2019-05-21 | 江西中医药大学 | 延龄草提取物及其中皂苷类化合物的制备方法及其在制备抗缺血性心脏病药物中的应用 |
-
1980
- 1980-02-26 JP JP2227880A patent/JPS56120700A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648430A (zh) * | 2015-10-22 | 2018-02-02 | 江西中医药大学 | 一种含延龄草甾体皂苷类有效成分胶囊制剂的制备方法及其在制备各类药物中的应用 |
| CN107890470A (zh) * | 2015-10-22 | 2018-04-10 | 江西中医药大学 | 一种含延龄草甾体皂苷类有效成分片剂的制备方法及其在制备各类药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56120700A (en) | 1981-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4338306B2 (ja) | 痴呆の予防または治療のためのステロイドサポニンの使用、及び新規なステロイドサポニン化合物 | |
| Schwartz et al. | Pharmacokinetics of sulfamethoxazole+ trimethoprim in man and their distribution in the rat | |
| Noreen et al. | Effect of Eriobotrya japonica on blood glucose levels of normal and alloxan-diabetic rabbits | |
| CN103191174B (zh) | 杜仲化学成分作为血管保护剂的新用途 | |
| CN105232891B (zh) | 延龄草提取物及其中皂苷类化合物的制备方法及其在制备抗缺血性心脏病药物中的应用 | |
| TWI284038B (en) | Polyhydroxylated benzene-containing compounds | |
| JPS6157808B2 (US08197722-20120612-C00042.png) | ||
| CN101759672B (zh) | 丹参丹酚酸b | |
| Ibrahim et al. | Editorial Review: Palytoxin: Mechanism of Action of a Potent Marine Toxin | |
| Naude et al. | Studies on South African cardiac glycosides. I. Isolation of toxic principles of Homeria glauca (W. & E.) NE Br. and observations on their chemical and pharmacological properties | |
| CN106928063A (zh) | 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用 | |
| JP2664699B2 (ja) | 外用剤 | |
| US2870140A (en) | Therapeutic agents derived from rauwolfia serpentina | |
| Dandiya et al. | A phytochemical and pharmacological study of Onosma bracteatum Wall | |
| Pastelin et al. | Cardiac effects of six actodigin (AY-22,241)-related semisynthetic glycosides | |
| JPH0329800B2 (US08197722-20120612-C00042.png) | ||
| Lockett | Changes in the flow and composition of the urine induced by the 18 monoacetate of D‐aldosterone, in cats | |
| CN102228427A (zh) | 一种牡荆素葡萄糖苷注射液及其制备方法 | |
| CN101229274B (zh) | 一种用于治疗或预防由高脂血症和/或高血压引起的勃起功能不全症的药物组合物 | |
| DE1912130A1 (de) | Cholinoleat und Mittel zur Behandlung von Krankheiten der Leber,der Gallenblase und der Bauchspeicheldruese | |
| JPS62132822A (ja) | 肝炎治療剤 | |
| CN107441045B (zh) | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 | |
| CN100368428C (zh) | 5α,8α-环二氧-24-二甲基胆甾-6-烯-3β-醇及其苷和酯、其制备方法和应用 | |
| US3922263A (en) | Hypoglycemic compound and method of preparing | |
| US3950518A (en) | Hypoglycemic composition and method of use |
